AstraZeneca gefitinib

USAN Gefitinib Trade Name Iressa AstraZeneca Launched 2003 M.W. 446.9... [Pg.29]

USAN Gefitinib Trade name Iressa AstraZeneca Approved 2002 (Japan)... [Pg.74]

Gallium nitrate (Gan/te-SoloPak) Gefitinib Iressa - AstraZeneca) Gemcitabine Gemzar- Lilly) Gemtuzumab Mylotarg- Wyeth)... [Pg.398]

Gefitinib (Iressa) lung cancer ISH. trial shows no overall survival advantage in a highly refractory population [press release 2004 Dec 17]. Available from http /Avww.astrazeneca-us.com/. [Pg.2381]

Another example of an EGER (HERl receptor) inhibitor is gefitinib (Iressa AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA). In May 2003, gefitinib (ZD1839) received accelerated approval by the US Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-smaU cell lung cancer (NSCLC), after failure of both platinum-based and docetaxel chemotherapies. [Pg.640]

Gefitinib (Iressa , AstraZeneca Teva) is a small-molecule inhibitor of the epidermal growth factor receptor s (EGFR, or erbBl) tyrosine kinase domain. It is used for non-small-cell lung cancer. [Pg.50]

AstraZeneca s gefitinib (Iressa) s core structure is a quinazoline. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated for the treatment of cancers. Several other protein kinase inhibitors also used the quinazoline ring as their core structure. They include OSI s erlotinib (Tarceva) and GSK s lapatinib (Tykerb). [Pg.16]

Big Chemical Encyclopedia